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Background: Brain concentrations of omega-3 docosahexaenoic acid (DHA, 22:6n-3)
have been reported to positively correlate with seizure thresholds in rodent seizure
models. It is not known whether brain DHA depletion, achieved by chronic dietary
omega-3 polyunsaturated fatty acid (PUFA) deficiency, lowers seizure thresholds in rats.
Objective: The present study tested the hypothesis that lowering brain DHA
concentration with chronic dietary n-3 PUFA deprivation in rats will reduce seizure
thresholds, and that compared to injected oleic acid (OA), injected DHA will raise seizure
thresholds in rats maintained on n-3 PUFA adequate and deficient diets.
Methods: Rats (60 days old) were surgically implanted with electrodes in the amygdala,
and subsequently randomized to the AIN-93G diet containing adequate levels of n-3
PUFA derived from soybean oil or an n-3 PUFA-deficient diet derived from coconut
and safflower oil. The rats were maintained on the diets for 37 weeks. Afterdischarge
seizure thresholds (ADTs) were measured every 4–6 weeks by electrically stimulating the
amygdala. Between weeks 35 and 37, ADTs were assessed within 1 h of subcutaneous
OA or DHA injection (600 mg/kg). Seizure thresholds were also measured in a parallel
group of non-implanted rats subjected to the maximal pentylenetetrazol (PTZ, 110
mg/kg) seizure test. PUFA composition wasmeasured in the pyriform-amygdala complex
of another group of non-implanted rats sacrificed at 16 and 32 weeks.
Results: Dietary n-3 PUFA deprivation did not significantly alter amygdaloid seizure
thresholds or latency to PTZ-induced seizures. Acute injection of OA did not alter
amygdaloid ADTs of rats on the n-3 PUFA adequate or deficient diets, whereas
acute injection of DHA significantly increased amygdaloid ADTs in rats on the n-3
PUFA adequate control diet as compared to rats on the n-3 PUFA deficient diet
(P < 0.05). Pyriform-amygdala DHA percent composition did not significantly differ
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between the groups, while n-6 docosapentaenoic acid, a marker of n-3 PUFA deficiency,
was significantly increased by 2.9-fold at 32 weeks.
Conclusion: Chronic dietary n-3 PUFA deficiency does not alter seizure thresholds in
rats, but may prevent the anti-seizure effects of DHA.
Keywords: after-discharge seizure threshold, amygdala, pentylenetetrazol, omega-3 deficiency, DHA
INTRODUCTION
Epilepsy is a progressive neurological disorder characterized
by self-sustained periods of neuronal hyperexcitability (1,
2). Approximately one third of people with epilepsy have
uncontrolled and persistent seizures despite being treated with
anti-seizure medications (3). These individuals are particularly
vulnerable to seizure-related psychiatric co-morbidities such
as depression and anxiety, and sudden unexplained death in
epilepsy (SUDEP) (4–6).
The main problem in people with epilepsy is that they have
a low seizure threshold in one or more parts of the brain (1, 7).
While mutations in several genes (e.g., sodium channel subunit
mutations) may underlie epileptic seizures (8), environmental
factors such as light or sound intensity may play a role in
provoking a seizure episode in seizure-prone individuals (9, 10).
Understanding factors that lower seizure thresholds may help
inform on strategies that enable better seizure control in people
with drug-resistant epilepsy.
Dietary lipids may also play a role in regulating seizure
thresholds in epileptic patients. In particular, omega-3
polyunsaturated fatty acids (n-3 PUFAs) derived from plants
(11) or seafood (12), were reported to raise seizure thresholds
in rodents (13–17). The main n-3 PUFA found in the brain is
docosahexaenoic acid (DHA, 22:6n-3). DHA regulates multiple
processes within the brain, including gene transcription,
neurotransmission, and the production of anti-inflammatory
lipid mediators involved in resolving neuroinflammation
(18–22).
DHA can be obtained preformed from the diet, or through
liver elongation and desaturation of dietary alpha-linolenic acid
(ALA, 18:3n-3) (23). ALA is thought to compete for elongation-
desaturation with omega-6 linoleic acid (LA, 18:2n-6), which
can be elongated-desaturated into arachidonic acid (AA, 20:4n-
6) and docosapentaenoic acid (22:5n-6; DPA n-6) (24). Rats
chronically fed an n-3 PUFA deficient diet show significant
reductions in brain DHA concentration and increases in n-6 DPA
(but not AA) concentration (25).
Mice fed an n-3 PUFA deficient diet for 30–34 days were
reported to have greater susceptibility to magnesium-dependent
audiogenic seizures thanmice fed an n-3 PUFA adequate diet (15,
26). Consistent with these rodent studies, one epidemiological
study reported a higher incidence of seizures in children born
to mothers consuming low (117 mg/day) or high (817 mg/day)
long-chain n-3 PUFAs during pregnancy as compared to children
of mothers consuming intermediate levels of n-3 PUFAs (400–
600 mg/day) (27). Another study reported reduced seizure
incidence in infants born to mothers who received 800 mg/day
of DHA during the second and third trimesters of pregnancy, as
compared to mothers not supplemented with DHA (i.e., given
a vegetable oil placebo) (28). Collectively, these studies suggest
that low intake of n-3 PUFAs may reduce seizure threshold and
increase the risk of seizure occurrence.
The present study tested the hypothesis that chronic dietary
n-3 PUFA deprivation will lower seizure thresholds in the
amygdala, a focus involved in the etiology of drug-resistant
complex-partial seizures (29, 30). Seizure thresholds were
measured over a period of 9 months, because we expected
brain DHA levels to decrease within several months of initiating
the n-PUFA deficient diets, due to the 4–12 weeks half-life
of DHA in the adult rat brain (31–33). Amygdaloid seizure
thresholds were also measured following acute oleic acid (OA,
18:1n-9) or DHA injection to n-3 PUFA adequate and deficient
rats, to test whether seizure thresholds would increase by DHA
administration. The present study also tested the effects of n-
3 PUFA deficiency in the pentyleneterazol (PTZ) model of
generalized tonic-clonic seizures in rats (34). Brain DHA and
n-6 DPA composition was measured in a parallel group of non-
seizure tested rats.
MATERIALS AND METHODS
Subjects and Treatments
Experimental procedures followed the Canadian Council on
Animal Care guidelines, and were approved by the Animal Care
Committee of the Faculty of Medicine of the University of
Toronto.
Male Wistar rats (Charles River, La Prairie, QC, Canada),
aged 53–60 days, were housed individually in transparent plastic
cages with corn-cob bedding in a 12 h light-dark cycle vivarium
maintained at 21◦C. Food (Teklad Global, 2018 18% Protein
Rodent Diet) and water were available ad libitum. All subjects
were handled for a period of 7 days, following arrival from the
breeding farm.
Two parallel experiments were then initiated as outlined in
Figures 1A,B and described in detail below. The first experiment
involved electrode implantations into the basolateral amygdala
of 20 rats, followed by repeated seizure threshold measurements
over a 34 week period during which the subjects were fed an
n-3 PUFA adequate or deficient diet (Figure 1A). These rats
were also treated with OA or DHA to test their effects on
seizure threshold under the two dietary conditions. The second
experiment involved a parallel group of non-implanted rats (n=
42) that were randomized to the n-3 PUFA adequate and deficient
diets. These subjects were sacrificed after 16 or 32 weeks of dietary
treatment to measure the effects of diet on brain DHA levels,
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FIGURE 1 | General experimental design for implanted (A) and non-implanted
(B) rats. The amygdala-implanted rats (B) were randomized to an n-3 PUFA
adequate or deficient diet for a total of 37 weeks. They were subjected to
repeated ADT measurements, once every 4–6 weeks, for 34 weeks. ADTs
were measured between weeks 35–37, following i.p., injection with 600 mg/kg
of oleic acid (OA) or docosahexaenoic acid (DHA). The non-implanted rats
(B) were randomized to the same diets for 33 weeks. Two-thirds of the
animals were sacrificed following 16 and 32 weeks of dietary treatment, and
one-third was subjected to pentylenetetrazol-induced seizures after 33 weeks
of dietary treatment.
or subjected to PTZ seizure testing after 33 weeks of treatment
(Figure 1B).
Procedure for Electrode Implantation
Twenty rats were surgically implanted with stainless steel bipolar
electrodes (MS303/1, Plastics One, Roanoke, VA, USA) aimed
at the right basolateral amygdala (n = 20), under isoflorane
anesthesia. The amygdala coordinates were as follows: anterior-
posterior, −2.8; medial-lateral (bregma), 4.6 (bregma); and
dorsal-ventral, −8.6 (skull surface at bregma). The incisor bar
was set and maintained in the horizontal position by aligning
bregma and lambda to the horizontal plane. The electrodes
were fixed to the skull with 3–4 stainless steel anchor screws
and acrylic dental cement (Nuweld, LD, Caulk). All subjects
were subcutaneously injected with buprenorphine analgesic
(0.05 mg/kg) and physiological saline (1 ml/kg) for rehydration
following surgery.
Afterdischarge Threshold (ADT)
Measurements
Baseline afterdischarge thresholds (ADTs) in the amygdala were
measured 8 weeks following surgery, using the ascending series
method (Figure 1A). Subjects were placed in a corn-bedded open
field chamber and connected to a Grass model S-88 stimulator
(Grass Instruments, Quincy, MA, USA), which delivered pulses
through the recording electrode. The subjects received a one-
second train of stimulation pulses at a frequency of 60Hz,
composed of a 1ms positive and 1ms negative phase separated
by 0.5ms. The initial stimulus intensity was 40 µA. The current
was increased in steps of 20 µA up to 400 µA, and then in
steps of 40 µA from 400 µA onwards, until an afterdischarge
was evoked. The interval between stimulations was 5min. The
same electrodes were used for stimulating and recording focal
electroencephalographic (EEG) activity.
Baseline ADT was measured again, 2 weeks later, after which,
the animals were randomized to the n-3 PUFA adequate or
deficient diets (see next section). ADTs weremeasured once every
4–6 weeks thereafter for 34 weeks. The second baseline ADT
measurement was used as the reference point of comparison
for assessing subsequent changes in seizure thresholds because
the first baseline threshold measurements are known to drop
drastically (but plateau to some extent) following the first
stimulation (16).
Diets Administration and ADT
Measurements
Amygdaloid subjects were started on the control n-3 PUFA
adequate diet or the experimental n-3 PUFA deficient diet, 1
week after the second baseline ADTmeasurement. The diets were
mixed every 2–3 days in our laboratory, and stored at 4◦C. The
cornstarch and sucrose components of the diets were obtained
from Disley Food Services (Scarborough, ON, Canada). The
oils were obtained from Loblaws Supermarkets (Toronto, ON,
Canada). Other ingredients (protein, fiber, vitamins, minerals
and antioxidant) were obtained from Dyets Inc. (Bethlehem, PA,
USA).
The control AIN-93G diet contained (g/kg): casein (200),
cornstarch (530), sucrose (100), soybean oil (70), cellulose
(50), vitamin mix (10), mineral mix (35), L-cysteine (3),
choline bitartrate (2.5) and tertbutyl hydroquinone (0.014).
The n-3 PUFA deficient diet contained identical macronutrient
composition, but the source of fat was derived from 24 g/kg of
safflower oil and 46 g/kg of coconut oil in lieu of the soybean
oil. The fatty acid composition of the AIN-93G control and n-3
PUFA deficient diets is presented in Table 1.
ADT Measurement Following DHA or Oleic
Acid Administration
ADTs were measured between weeks 35–37 in the amygdaloid
implanted subjects following OA or DHA injection (Figure 1A).
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TABLE 1 | Fatty acid composition (% of total fatty acids) of the n-3 PUFA
adequate and n-3 PUFA deficient diets.
n-3 PUFA adequate n-3 PUFA deficient
6:0 1.04 ± 1.80 0.72 ± 1.25
7:0 0.20 ± 0.22 0.16 ± 0.08
8:0 0 ± 0 7.96 ± 0.25
10:0 0.09 ± 0.08 5.56 ± 0.13
12:0 0.10 ± 0.09 35.04 ± 0.56
14:0 0.23 ± 0.01 11.71 ± 0.12
15:0 0.15 ± 0.01 0.11 ± 0.003
16:0 12.34 ± 0.23 8.23 ± 0.10
18:0 3.71 ± 0.12 2.24 ± 0.01
20:0 0.29 ± 0.01 0.12 ± 0.01
22:0 0.57 ± 0.32 0.18 ± 0.07
24:0 0.05 ± 0.08 0 ± 0
Total SFAs 18.77 ± 1.40 72.04 ± 0.36
18:1 t9 0 ± 0 0.092 ± 0.003
18:1 c9 16.28 ± 0.20 7.22 ± 0.08
18:1 c11 1.22 ± 0.02 0.31 ± 0.006
19:1 c7 0.297 ± 0.003 0 ± 0
22:1 n9 0 ± 0 0.07 ± 0.06
Total MUFAs 17.84 ± 0.25 7.70 ± 0.11
18:2 n6 53.58 ± 0.91 19.54 ± 0.26
18:3 n6 0.09 ± 0.08 0.12 ± 0.002
20:2 n6 0.18 ± 0.04 0 ± 0
Total n-6 PUFAs 53.85 ± 0.96 19.66 ± 0.27
18:3 n3 9.53 ± 0.21 0.60 ± 0.02
Total n-3 PUFAs 9.53 ± 0.21 0.60 ± 0.02
Data are mean± SD of n= 3 representative samples per diet. SFAs, saturated fatty acids;
MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids.
The rats received a subcutaneous injection of DHA (600 mg/kg)
or an equivalent dose of OA control 1 week after the last
ADT was measured on week 34. A week later, treatments were
switched, meaning that rats that received OA, received DHA.
ADTs were measured following injection as described above.
ADT measurements were initiated within 15min post-injection.
This ensured that each subject reached its expected ADT by∼1 h
post-injection, in view of a study showing that it takes 1 h for
DHA to increase seizure threshold (35).
The rationale for the 600 mg/kg dose is based on body weight.
We had previously reported that DHA raises seizure thresholds
in the PTZ seizure model 1 h following injection at a dose of
300–400 mg/kg in rats weighing 200–300 g (35–37). The rats in
the present study weighed ∼834 g at the time of seizure testing.
Because unesterified DHA has a short plasma half-life and high
volume of distribution associated with increased adiposity in
heavier rats, the higher DHA dose of 600 mg/kg was selected
to account for the greater body weight that likely increases the
volume of distribution.
To compare the effects of OA and DHA on seizure thresholds,
we subtracted the ADT measured on weeks 35 and 36, following
OA or DHA injection, from the previous ADT on week 34, and
the ADT following OA or DHA injection on week 37 from the
ADT measured on weeks 35 and 36. In other words, the change
in ADT was measured by subtracting the ADT following OA or
DHA injection, from the prior ADT level.
Dietary Treatment to Rats Used for
Determining Brain Fatty Acid Composition
A parallel group of subjects were obtained from the breeding
farm and placed on the n-3 PUFA adequate (n = 21) or deficient
diets (n = 20) at the same time as the implanted animals
(Figure 1B). They were handled in a similar manner upon arrival
and throughout the course of the experiment, being placed in
an open field for 30min once a month. Two-thirds of these
subjects were sacrificed at 16 and 32 weeks (n = 7 per group
per time-point) post diet initiation with CO2 asphyxiation. The
remaining one-third (n = 6–7 per group) was sacrificed at 33
weeks as described in the following section. The rationale for
sacrificing the rats after 16 or 32 weeks of dietary treatment is
based on the 4–12 weeks half-life of brain DHA, which led us
to predict that a duration of 3–4 half-lives would be required to
observe measurable effects of diet on brain DHA levels (31–33).
The brains were excised immediately after CO2 asphyxiation, and
dissected to separate piriform-amygdala from a 1mm coronal
section of the left hemisphere. The dissected pyriform-amygdala
samples were stored in a minus 80◦C freezer until they were
subjected to fatty acid analysis as described below.
PTZ Seizure Testing in Rats on the n-3
PUFA Adequate and Deficient Diets
The PTZ seizure test was performed on the remaining group
of subjects with no implanted electrodes following 33 weeks of
dietary treatment (Figure 1B; n = 14). Subjects were injected
intraperitoneally with 110 mg/kg of PTZ, and observed in an
open field for 10min. This dose was chosen because it reliably
induced tonic-clonic seizures in a separate group of subjects that
were of the same age. The latency to the onset of myoclonic jerks
and tonic-clonic seizures was determined by two observers, of
whom one was blinded and the other was handling the animals.
Subjects were euthanized with sodium pentobarbital (100 mg/kg)
upon visibly showing tonic-clonic convulsions.
Sacrifice and Tissue Fixation
Electrode-implanted subjects were deeply anesthetized with
sodium pentobarbital (100 mg/kg), and subjected to a direct
current of 100 µA for 30 s in order to lesion the site of the
electrode implant for subsequent histological evaluation of the
position of the electrode tip. The subjects were then decapitated,
and the brains were dissected quickly and stored in formalin for
a few weeks to ensure complete fixation of the tissue. The brains
were then transferred to 20% sucrose solution containing 0.1%
sodium azide and stored at 4◦C for a few weeks until they were
histologically examined.
Histological Confirmation of Electrode
Placement
The right hemisphere that contained the implanted electrode
was used for histological confirmation as previously described.
In brief, the hemispheres were chilled in isopentane on dry ice
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and sectioned using a cryostat (Leica Instruments, Willowdale,
Ontario, Canada) maintained at −25◦C. Coronal sections were
obtained at a thickness of 40µm and mounted onto gelatin
coated glass slides. The electrode tract was visible to the naked
eye, so sections were collected close to where the tract ended,
and subsequently confirmed under light microscopy (Research
Analysis System Model 421251; Amersham, MI). Subjects with
misplaced electrodes were excluded from subsequent data
analysis.
Fatty Acid Analysis of the
Pyriform-Amygdala
Total lipids were extracted from pyriform-amygdala by the
method of Folch et al. (38) after being weighed to the nearest
tenth of a milligram. The weighed samples were grinded in 6.5ml
of 0.9% KCl using a glass-grinder, and washed twice with 5ml
methanol, and twice with 10ml of chloroform. Diheptadecanoyl
L-α-phosphatidylcholine (Sigma, St. Louis, MO) in chloroform
was added as an internal standard to the total lipid extracts,
which were then dried under nitrogen and reconstituted in 2ml
of chloroform.
Total lipids directly methylated in 14% methanolic BF3
(2mL) and hexane (2ml) at 100◦C for 1 h. The samples were
allowed to cool at room temperature for 10min and centrifuged
at 1,200 g following the addition of deionized water (2ml).
The upper hexane layer containing fatty acid metyl esters
(FAMEs) was reconstituted in 50µl hexane and analyzed by
gas-chromatography as described in the following section.
Fatty Acid Methyl Ester Analysis by
Gas-Chromatography
FAMEs were analyzed on a Varian-430 gas chromatograph
(Varian, Lake Forest, CA, USA) equipped with a Varian
FactorFour capillary column (VF-23ms; 30m × 0.25mm i.d. ×
0.25µm film thickness) and a flame-ionization detector. FAMEs
were injected in splitless mode. The carrier gas was helium, set
to a constant flow rate of 0.7 ml/min. The injector and detector
ports were set at 250◦C. FAMEs were eluted using a temperature
program set initially at 50◦C for 2min, increased at 20◦C/min to
170◦C held at 170◦C for 1min, increased at 3◦C/min to 212◦C
and held at 212◦C for 5min. Peaks were identified by retention
times of authentic FAME standards of known composition (Nu-
Chek-Prep, Elysian, MN).
Dietary Fatty Acid Analysis
The fatty acid composition of the n-3 PUFA adequate and
deficient diets was also determined by gas-chromatography.
Total lipids were first extracted from ∼0.5 g of powdered
diet in chloroform/methanol (2:1 v/v) after adding 2mg of
unesterified heptadecanoic acid as an internal standard (Sigma,
St. Louis, MO). Saline (0.9% w/v, 2ml) was added to separate
polar compounds. The bottom layer containing total lipids was
transferred to test-tubes. A portion of the extract was dried under
nitrogen, reconstituted in 2ml of hexane, and directly methylated
with 2ml of 14% boron trifluoride in methanol at 100◦C for 1 h.
The hexane layer was extracted and FAMEs were analyzed by
gas-chromatography as described above.
Data Presentation and Statistical Analysis
The data are presented as means ± SD. Data analysis was
performed using Sigma Stat v.3.2 (Jandel Corporation) or
Graphpad Prism v 5.0 (La Jolla, CA). A two-way repeated
measures analysis of variance (ANOVA) was used to determine
the effects of diet and time on body weight, ADT, seizure duration
and seizure score. A two-way ANOVA was used to test the
effect of diet and time on pyriform-amygdala DHA and n-6 DPA
composition. Due to the small sample size, the Mann-Whitney
U-test was used to assess differences in the latency to PTZ-
induced seizures between the n-3 PUFA adequate and deficient
groups. Statistical significance was accepted at P < 0.05.
RESULTS
Electrode Placements
Although, the surgeries were aimed at placing the electrodes
within the basolateral amygdala, subjects with electrodes falling
within the amygdaloid complex were included in the analysis.
Electrodes were successfully implanted within the amygdala in 5
out of 8 n-3 PUFA adequate control rats and 4 out of 8 n-3 PUFA
deficient rats. Subjects with electrodes misimplanted outside the
amygdaloid complex were, therefore, excluded from subsequent
analyses.
In the successfully implanted subjects, electrodes were within
the basolateral amygdala for 3 (out of 5) and 2 (out of 4)
subjects within the n-3 PUFA adequate and deficient groups,
respectively. The electrodes for the remaining subjects were
within the amygdala, but slightly medial or anterior to the
basolateral amygdala. We were not able to compare differences in
ADTs within the different amygdala foci due to the small sample
size, which is why we accepted subjects with successful implants
anywhere within the amygdala. This is also consistent with our
primary hypothesis, which aimed to test the effects of diet on
amygdaloid seizure thresholds.
FIGURE 2 | Effects of chronic n-3 PUFA deficiency on body weight over time.
Rats were placed on a n-3 PUFA adequate (control) or n-3 PUFA deficient diet.
Data are mean ± SD of n = 5 n-3 PUFA adequate controls and 4 n-3 PUFA
deficient rats. Two-way repeated measures ANOVA showed a significant effect
of time on body weight (P < 0.0001). There was no significant effect of diet on
body weight (P > 0.05). Subjects’ weights increased over time, regardless of
diet.
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Body Weight
The data related to body weight of implanted rats from the start
of the baseline ADT measurements and throughout the 34 weeks
period of threshold measurements is shown in Figure 2. A two-
way repeated measured ANOVA showed a significant effect of
time (P < 0.0001) but not of dietary treatment (P > 0.05) on
body weight. As shown in Figure 2, both n-3 PUFA adequate and
deficient rats gained weight over time. There were no significant
differences in body weight between the groups at any time point.
Effect of Dietary n-3 PUFA on Amygdaloid
ADT and Seizure Duration
Seizures were successfully recorded at baseline (“week 0”) and at
4, 10, 16, 20, 22, 26 and 34 weeks thereafter. Recordings were
obtained for all subjects with amygdala implants, except for one
n-3 PUFA adequate control rat on weeks 22, 26, and 34 and one
n-3 deficient rat on weeks 10, 16, and 20. These two subjects did
not show an afterdischarge when measured during these time
periods, probably due to a transient (but unconfirmed) infection.
We were not able to retrieve raw ADT files for one control rat on
week 16 and one n-3 deficient rat on week 20. ADTs that were
not successfully obtained for these 4 rats during the 1–3 time-
points were not included in the statistical analysis. Thus, ADTs
successfully recorded for these 4 rats during other weeks, as well
as the rest of the amygdala-implanted subjects, were included in
the statistical analysis.
The data related to ADT (µA), percent change in ADT from
baseline and seizure duration over the 34 week measuring period
are presented in Figures 3A–C. Two-way repeated measures
ANOVA showed a significant effect of time but no effect
of treatment or interaction between time and treatment for
ADT, % change in ADT and seizure duration. As shown
in Figure 3, ADT (Figure 3A) and the % change in ADT
(Figure 3B) decreased gradually over time in both n-3 adequate
and deficient rats, whereas seizure duration increased over
time (Figure 3C). A peculiar observation is that absolute
ADT values appeared to decrease more for the n-3 PUFA
adequate group at 26 and 34 weeks (Figure 3A), but after
correcting for the small but insignificant differences in baseline
ADT between the two groups, this effect was no longer seen
(Figure 3B).
ADT Following OA or DHA Injection
OA or DHA (600 mg/kg) were injected subcutaneously to n-
3 PUFA adequate and deficient rats between weeks 35 and 37,
to test whether DHA raises ADT. In particular, we wanted to
address whether ADTs increased in n-3 deficient rats following
DHA injection.
Figure 4 shows the change in ADT and seizure duration
following s.c., injection of n-3 PUFA adequate and deficient
rats with OA or DHA. Two-way ANOVA revealed a significant
interaction between diet and fatty acid injection (P = 0.048),
but no significant main effect of diet or injection on ADT
(Figure 4A). Post-hoc analysis with Bonferroni’s post-hoc test
indicated that the change in ADT following DHA treatment
was significantly higher in rats on the n-3 adequate group as
compared to rats on the n-3 deficient group (P < 0.05). The
change in ADT following OA injection was not significant
between n-3 adequate or deficient rats. Also, no significant
differences between OA and DHA injection were observed.
Two-way ANOVA showed no significant effect of diet or fatty
acid (OA or DHA) injection on seizure duration (Figure 4B).
Also, no significant interaction was detected.
Latency to PTZ-Induced Seizure Onset
Following 33 Weeks of Treatment With an
n-3 PUFA Adequate or Deficient Diet
Body weights measured at the time of seizure testing were
not significantly different between the two groups (n-3 PUFA
FIGURE 3 | Effect of chronic n-3 PUFA deficiency on (A) ADT (µA), (B)
percent change in ADT over time and (C) seizure duration. ADTs and
seizure duration were recorded for 34 weeks from rats maintained on the n-3
PUFA adequate diet (n = 5) or n-3 PUFA deficient diet (n = 4). Two-way
repeated measures ANOVA showed a significant effect of time but no effect of
treatment or interaction between time and treatment on ADT, % change in
ADT and seizure duration. ADT (A) and the % change in ADT (B) decreased
gradually over time in both n-3 adequate and deficient rats, whereas seizure
duration increased over time (C).
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adequate, 873 ± 125 g, n = 7; n-3 PUFA deficient 789 ± 116 g,
n= 6, P = 0.29 Mann-Whitney U-test).
The data related to the onset of myoclonic jerks and tonic-
clonic seizures following PTZ administration to non-implanted
rats maintained on the n-3 PUFA adequate or deficient diet are
presented in Figure 5. One rat from the PUFAn-3 deficient group
did not seize within the 10min observation period so it was not
included in the statistical analysis. As shown in Figure 5A, the
latency to mycolonic jerks in the rats that seized did not differ
significantly between the groups (P = 0.15 by Mann-Whitney
U-test). The latency to tonic-clonic seizures (Figure 5B) was
lower by 57% in the n-3 PUFA deficient group as compared to
controls, but the difference was not statistically significant (P =
0.06).
Piriform-Amygdala DHA and N-6 DPA
Composition
Piriform-amygdala DHA and n-6 DPA were measured in a
parallel group of non-electrode implanted subjects administered
FIGURE 4 | Change in ADT 1 h post s.c. injection of OA or DHA (600 mg/kg)
to rats fed an n-3 PUFA adequate or deficient for 37 weeks. Rats of each
dietary group randomly received 600 mg/kg of oleic acid (OA) or
docosahexaenoic acid (DHA) approximately 1 week after the last ADT was
taken on week 34. ADTs and seizure duration were measured within 1 h of fatty
acid treatment. One week later, the treatments were switched (i.e. rats that
received OA now received DHA), and ADTs were measured within 1 h of fatty
acid treatment. The difference in ADT following OA and DHA treatment of each
subject, per diet, was determined (i.e., DHA ADT—OA ADT) using the prior
ADT as a reference point. As shown in (A), two-way ANOVA revealed no main
effect of diet or fatty acid treatment on the change in ADT. A significant diet
and fatty acid treatment interaction was detected (P < 0.05). Post hoc analysis
of the means with Bonferroni’s post-hoc test indicated that the change in ADT
following DHA treatment was significantly greater in rats on the n-3 adequate
diet as compared to rats on the n-3 PUFA deficient diet (*P < 0.05). No
significant main effects or interaction were detected for seizure duration (B).
the n-3 PUFA adequate or deficient diets for 16 and 32 weeks.
Figure 6 shows piriform-amygdala DHA (6-A) and n-6 DPA (6-
B) composition, expressed as percentage of total fatty, of rats fed
an n-3 PUFA adequate or deficient diet for 16 and 32 weeks. A
two-way ANOVA followed by Benferroni’s post-hoc was used to
assess the effect of diet and time on pyriform-amygdala DHA and
n-6 DPA% composition.
There was no significant effect of diet, time or interaction
between diet and time on DHA percent composition. There
FIGURE 5 | Latency to the onset of myoclonic jerks and tonic clonic seizures
following PTZ administration (110 mg/kg, i.p.) to rats treated with an n-3 PUFA
adequate or deficient diet for 33 weeks. One rat from the n-3 PUFA deficient
group was excluded because it did not seize within the 10min observation
period. Data are mean ± SD of n = 7 n-3 PUFA adequate and n = 5 n-3 PUFA
deficient subjects. (A) Latency to the onset of myoclonic jerks. A
Mann-Whitney U was used to compare latencies. The latency to the onset of
myoclonic jerks did not differ significantly between the groups (P = 0.15).
(B) Latency to the onset of tonic-clonic seizures. A Mann-Whitney U was used
to compare latencies. The latency to the onset of tonic-clonic seizures was
lower in the n-3 deficient group as compared to the adequate group. This
difference, however, was not statistically significant (p = 0.06).
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was a significant effect of time (P = 0.0261) and diet (P =
0.0006) on n-6 DPA percent composition, but no significant
interaction was detected (P = 0.0997). Post-hoc comparison of
the means indicated that the difference between the n-3 adequate
and deficient groups at 32 months was statistically significant. N-
6 DPA was 2.9-fold higher in the n-3 PUFA deficient group as
compared to the n-3 PUFA adequate group.
DISCUSSION
The present study showed that chronic dietary n-3 PUFA
deficiency, achieved by removing ALA from the diet, did not
significantly alter amygdaloid seizure thresholds or latency to
PTZ-induced seizures. Acute OA injection did not alter ADTs,
FIGURE 6 | DHA (A) and n-6 DPA (B) % of total fatty acids in
piriform-amygdala of rats fed an n-3 PUFA adequate or deficient diet for 16
and 32 weeks. Data are mean ± SD of n = 7 per diet group per time-point for
each fatty acid, except n-6 DPA, for which n = 6 in control rats at 32 weeks
because it was not detected in one sample. A two-way ANOVA followed by
Benferroni’s post-hoc was used to assess the effect of diet and time on
pyriform-amygdala DHA and n-6 DPA % composition. There was no significant
effect of diet, time or interaction between diet and time on DHA percent
composition. There was a significant effect of time (P = 0.0261) and diet (P =
0.0006) on n-6 DPA percent composition, but no significant interaction was
detected (P = 0.0997). Post-hoc comparison of the means indicated that the
difference between the n-3 adequate and deficient group was significant at 32
weeks (**P < 0.01).
whereas DHA increased amygdaloid ADTs in the n-3 PUFA
adequate group relative to the n-3 PUFA deficient group. Chronic
PUFA n-3 deficiency increased pyriform-amygdala n-6 DPA
percent composition without altering DHA composition.
Our findings do not support the hypothesis that n-3 PUFA
deficiency lowers seizure thresholds in adult rats. This may be
related to the fact that the amygdala-pyriform DHA composition
was not reduced following dietary n-3 PUFA deprivation.
Previous studies reported a significant reduction in cortical
and whole brain DHA concentrations and percent composition
following chronic n-3 PUFA deficiency (39–41). The lack of
changes in DHA composition in the pyriform-amygdala suggests
that this brain region may be less sensitive to the effects of dietary
n-3 PUFA manipulation as compared to other brain regions.
Consistent with this suggestion, we reported that chronic fish
oil supplementation to rats for 6 months did not significantly
increase piriform-amygdala DHA concentration (16).
Another possibility accounting for the lack of change in
piriform-amygdala DHA composition is that the n-3 PUFA
deficient diet was initiated during adulthood (at 5 months of age).
Other studies initiated n-3 PUFA deficiency during development
or at weaning (∼21 days post-partum) (39–41). In rats, DHA
accretes in the brain during the first 29 days of life, and early
n-3 PUFA deficiency interferes with brain DHA accretion and
concentration (42). The extent of brain DHA depletion when
dietary n-3 PUFA deficiency is initiated during adulthood, and
after DHA accretion rate has reached steady-state, is not known.
It is possible that adipose tissue contributes to maintaining
pyriform-amygdala DHA status throughout adulthood when
n-3 fatty acids are absent from the diet (43). An alternative
but unconfirmed hypothesis is that DHA turnover within the
pyriform-amygdala complex is slow compared to other brain
regions such as the cortex. Regional differences in brain DHA
turnover in relation to concentration should be further examined
in future studies.
N-6 DPA, a marker of n-3 PUFA deficiency was significantly
increased 32 weeks after the rats were started on the n-3 PUFA
deficient diet. It is unlikely that n-6 DPA altered ADTs, because it
was reported to have no effect on excitatory hippocampal sharp
waves ex vivo (44). Future studies should confirm these findings
in vivo, however.
Pages et al. reported that mice fed an n-3 PUFA deficient diet
for 30–34 days were more susceptible to magnesium-dependent
audiogenic seizures than mice fed an n-3 PUFA adequate diet
(15, 26). We did not observe significant changes in amydgaloid
afterdischarge or PTZ seizure thresholds following n-3 PUFA
deprivation in the present study. Differences in study outcomes
are likely due to the seizuremodel used. The studies by Pages et al.
used a magnesium deficient diet, which may have lowered seizure
thresholds sufficiently for audiogenic provocation (15, 26).
Acute DHA injection increased amygdaloid seizure thresholds
in rats on the n-3 PUFA adequate diet, but not in rats on the n-3
PUFA deficient diet, while OA had no significant effect on ADTs.
The increase in amygdaloid seizure thresholds following DHA
injection in the n-3 adequate group is consistent with previous
studies which showed that injected or dietary DHA raises seizure
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thresholds in rats on an n-3 adequate diet (16, 17, 36, 37, 45,
46).
In our previous studies, the increase in seizure latency
following acute DHA injection was attributed to the increase
in plasma unesterified DHA concentration (37), the form
available for brain uptake (32, 47, 48). The lack of significant
effect of unesterified DHA on amygdaloid ADTs in the n-3
PUFA deficient group, is likely because injected DHA did not
increase plasma unesterified DHA concentrations to therapeutic
levels. Plasma unesterified DHA before and after acute DHA
administration to n-3 PUFA adequate and deficient rats was
not measured in the present study, a limitation which should
be addressed in future studies. Unesterified DHA is known to
reduce neuronal excitability by acting on GABA or voltage gated
ion channels (44, 49–51), or through its oxygenated metabolites
such as neuroprotectin D1 (21), which were reported to reduce
electrically induced hippocampal excitability in rodents (52).
TheNorth American diet may be low inDHA (53–55), but it is
not omega-3 deficient per se. Although extreme n-3 deficiency as
modeled in the present study is not likely to be clinically prevalent
(53–55), this study demonstrates the importance of dietary n-3
PUFA status as a potential modifier of the anti-seizure effects of
DHA. It is not clear, however, as to whether people with epilepsy
have low or deficient n-3 fatty acid intake or circulating DHA
levels.
The main limitation of this study is the low sample size. While
the repeated stimulations over time confirm no changes in ADT
between the diets, the PTZ and acute OA and DHA injection
experiments were only performed once. These studies should be
reproduced with a larger number of subjects. Another limitation
is that not all electrodes were within the intended basolateral
amygdala target; some were medial or lateral but were within
the amygdala. Thus, our findings cannot be generalized to the
basolateral amygdala or specific structures within.
In conclusion, dietary n-3 PUFA deprivation for 8–9 months
did not alter amygdaloid seizure thresholds or the latency to PTZ-
induced seizures. Injected DHA, however, raised amygdaloid
seizure thresholds in rats on the n-3 PUFA adequate diet, but had
no effect in rats on the n-3 PUFA deficient diet, suggesting that
dietary n-3 PUFA status may modulate the anti-seizure effects of
DHA. Clinical assessment of dietary n-3 fatty acid background
and circulating DHA status is warranted in intervention studies
addressing the role of DHA supplementation in people with
epilepsy. Understanding the role of DHA in raising seizure
thresholds may reduce seizure incidence and the risk of SUDEP
in at-risk individuals (56–58).
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